Company Filing History:
Years Active: 2021-2024
Title: Garth Hamilton: Innovator in T Cell Modification
Introduction
Garth Hamilton is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly in the modification of T cells for therapeutic applications. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.
Latest Patents
Hamilton's latest patents focus on the modification of T cells to enhance their therapeutic potential. One of his key inventions relates to modified T cells that inducibly express a bioactive molecule, such as IL-7, while constitutively expressing an antigen receptor that binds to tumor antigens. These modified T cells may include a nucleic acid construct that comprises a first nucleotide sequence encoding the bioactive molecule and a second nucleotide sequence encoding the antigen receptor. The constructs are designed with an inducible promoter linked to the first nucleotide sequence and a constitutive promoter linked to the second nucleotide sequence. This innovative approach provides new avenues for therapeutic methods and applications in cancer treatment.
Career Highlights
Garth Hamilton is currently associated with Adaptimmune Limited, where he continues to work on groundbreaking research in T cell modification. His expertise and innovative mindset have positioned him as a key player in the field of immunotherapy.
Collaborations
Hamilton collaborates with talented individuals such as Jonathan Silk and Claire Gueguen, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Garth Hamilton's contributions to T cell modification represent a significant advancement in cancer therapy. His innovative patents and collaborative efforts are set to make a lasting impact in the field of immunotherapy.